Latest Regulatory Updates News

Clinuvel Pharmaceuticals has reported a robust financial year ending June 2025, marked by solid revenue growth and sustained profitability, while advancing its clinical pipeline and maintaining a strong balance sheet.

Telix Pharmaceuticals has received a Complete Response Letter from the FDA for its TLX250-CDx diagnostic agent, citing manufacturing concerns. The company plans immediate remediation and maintains its 2025 revenue guidance.

29Metals has successfully moved its application for a new tailings storage facility at Capricorn Copper into detailed assessment, marking a critical step toward restarting operations sustainably.

Nyrada Inc has responded to ASX inquiries confirming the timely and compliant disclosure of positive safety data from its Phase I clinical trial of Xolatryp. The company detailed the timeline of its awareness and release of information, affirming adherence to continuous disclosure rules.

Life360, Inc. reported a return to profitability in Q2 2025, driven by strong subscription growth and strategic partnerships, while also announcing a leadership transition and issuing $320 million in convertible notes.

AVITA Medical has filed its Q2 2025 Form 10-Q, reaffirming its leadership in acute wound care with its FDA-approved RECELL System and expanding international footprint.

AVITA Medical’s Q2 2025 update reveals a temporary setback in RECELL demand due to Medicare reimbursement delays, offset by strong revenue growth and promising clinical data. The company anticipates recovery and renewed growth in the second half of the year.

BlackRock Investment Management (Australia) Limited has announced the Distribution Reinvestment Plan (DRP) prices for three major Australian iShares ETFs for the July 2025 distribution period, alongside important investor compliance reminders.

DMC Mining Limited has extended the closing date of its public share offer to mid-September due to delays in securing exploration licences for key projects in Guinea. The company plans further regulatory updates as it awaits final approvals.

Nyrada Inc. has raised $8.25 million through a strategic placement to fund its upcoming Phase IIa clinical trial of Xolatryp for acute myocardial infarction, positioning the company for a pivotal year ahead.

Prescient Therapeutics has raised nearly $10 million through a placement and share purchase plan to advance its promising PTX-100 targeted cancer therapy into pivotal clinical stages.

Atlas Arteria reported a robust 10.7% increase in Q2 2025 toll revenue, driven by strong traffic growth and toll hikes, while the French government reaffirmed its backing of the concession model with regulatory updates expected later this year.